Key takeaways
- The FDA states semaglutide sodium and acetate are unauthorized chemical salts, not the approved base active ingredient.
- Compounding with these salt forms fails federal bulk drug substance requirements under sections 503A and 503B.
- The FDA issued over 50 warning letters targeting GLP-1 compounders for misbranding unauthorized salt forms.
- With the official semaglutide shortage over as of early 2025, pharmacies have no legal loophole to compound copies using these salts.
What happened
The U.S. Food and Drug Administration (FDA) has issued a direct warning to compounding pharmacies stating that semaglutide sodium and semaglutide acetate are unauthorized chemical salts that cannot be legally compounded. In regulatory communications highlighted by the Health Law Alliance, the agency clarified that these salt forms are entirely different active ingredients from the approved base form used in commercial GLP-1 medications.
Why it matters
For US consumers purchasing compounded semaglutide online, this clarification draws a sharp line between legal, high-quality compounding and unauthorized chemical substitutes. When brand-name shortages resolved, some pharmacies turned to these cheaper or more accessible salt forms to keep up with demand.
However, because these salts do not share the validated safety and efficacy profile of the approved drug, using them introduces major clinical risks. For telehealth buyers, this development means that checking whether a provider’s partner pharmacy uses "semaglutide base" rather than "semaglutide sodium" or "semaglutide acetate" is now a critical safety step. Pharmacies continuing to distribute these unauthorized salts face severe regulatory exposure, including FDA misbranding charges, state board of pharmacy complaints, and civil liability.
What the data says
The regulatory framework governing compounding is highly specific about what bulk drug substances can be used. Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a bulk substance must meet one of three criteria to be used in compounding:
- It must have an official United States Pharmacopeia (USP) or National Formulary (NF) monograph.
- It must be an active component of an FDA-approved drug.
- It must appear on the FDA’s approved bulk drug substances list.
According to the FDA, semaglutide base meets the second requirement because it is the active ingredient in approved brand-name injections. In contrast, semaglutide sodium and semaglutide acetate fail all three prongs. They are not components of any approved drug, they do not have a USP or NF monograph, and they do not appear on any federal bulks list.
The FDA formally warned the National Association of Boards of Pharmacy of this lack of legal basis on April 27, 2023. This was followed by a massive enforcement wave on September 9, 2025, when the FDA sent more than 50 warning letters to GLP-1 compounders and online sellers, citing misbranding violations under sections 502(a) and 502(bb) of the Act for claiming these salts were identical to the approved base drug.
How it compares
The legal landscape for compounded GLP-1 drugs changed dramatically when the FDA resolved the official semaglutide shortage on February 21, 2025. During the shortage, state-licensed 503A pharmacies and 503B outsourcing facilities could rely on a federal exception to compound copies of commercial drugs.
However, the FDA's declaratory order established strict wind-down windows that closed on April 22, 2025, for 503A pharmacies and May 22, 2025, for 503B facilities. Since those deadlines passed, the shortage-based justification for compounding semaglutide has vanished, leaving compounders who use unauthorized salt forms highly vulnerable to prosecution.
For buyers comparing options on CompareRx, this highlights a massive difference in quality standards between top-tier telehealth providers—who source exclusively from accredited 503A pharmacies using pure semaglutide base—and grey-market peptide websites selling unauthorized, unlabeled salts.
How this fits the bigger picture
This crackdown is part of a broader federal push to regulate the booming online medical weight-loss market. We have previously covered how the regulatory environment is squeezing the supply chain in our analysis of how the FDA limits bulk GLP-1 compounding. As the government systematically closes loopholes, operators who bypass standard clinical channels are finding their options restricted.
This regulatory tightening is particularly urgent given patient behavior. A peer-reviewed study we analyzed revealed that 48% of GLP-1 users turn to social media over medical professionals for clinical advice. This reliance on unverified online sources leaves patients highly susceptible to ordering from unregulated telehealth startups or peptide websites that discreetly ship dangerous salt-form versions of semaglutide. As the FDA continues to issue warnings, patients must learn to navigate these clinical differences to protect their health.
To find safe, vetted, and legally compliant medical weight-loss programs that use legitimate sourcing practices, you can explore our comprehensive list of GLP-1 providers.
What happens next
State boards of pharmacy are actively executing parallel enforcement measures alongside the FDA. For example, the Mississippi Board of Pharmacy has issued written warnings stating that salt-form compounding does not comply with federal bulk substance requirements. Meanwhile, New Jersey’s pharmacy board has banned licensees from using semaglutide salts entirely, even if the pharmacy possesses a valid certificate of analysis from an FDA-registered facility.
Moving forward, the FDA is expected to continue auditing compounding facilities and sending warning letters to online telehealth platforms that misbrand their weight-loss programs. Consumers should expect smaller, non-compliant compounding operations to shut down, while established telehealth providers will continue to consolidate their partnerships with highly regulated 503A pharmacies.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting or changing any medication regimen.